Nigral biochemical and structural alterations following subacute exposure to MPTP in mice.
MPTP exposure in Swiss mice led to significant neurobehavioral and biochemical changes, indicating its utility as a model for studying neurotoxicity.
Where it sits
this study against the rest of the humanin corpusSummary and findings
This study evaluated the effects of MPTP exposure on biochemical and structural changes in the substantia nigra of Swiss mice. Mice received either saline or MPTP (30 mg/kg i.p.) for 5 days, followed by assessments of neurobehavioral performance and various biochemical markers. Significant alterations were observed in neurobehavioral performance and oxidative stress biomarkers post-exposure.
Abstract
<h4>Background</h4>The substantia nigra is the critical part of the midbrain responsible for movement-related functions. Nigral alterations have been associated with neurological conditions related to movement disorders, including Parkinson's disease (PD). 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a toxin commonly used as a model of PD due to its selective nature of destroying dopaminergic neurons. However, toxicity varies among different animals and strains. Therefore, this study aimed to assess a comprehensive multi-level profile of early dopaminergic dysfunction by evaluating behavioural, biochemical, mitochondrial, neuroinflammatory, and histological assessments to characterise early nigrostriatal alterations in Swiss mice following subacute MPTP exposure.<h4>Methodology</h4>Twelve (12) adult male mice were randomly divided into two groups of six (6) mice each. Group I (control) was administered normal saline (1 ml/kg i.p.), while group II was administered MPTP (30 mg/kg i.p.) daily for 5 consecutive days. Twenty-four (24) hours following the last MPTP administration, the mice were assessed for neurobehavioural performance using the beam walk, pole, and traction test. Assessments of oxidative stress biomarkers [malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT) and reduced glutathione (GSH)], mitochondrial complex 1 activity, neuroinflammatory markers (IL-1β and TNF-α), brain-derived neurotrophic factor (BDNF), monoamine oxidase B (MAO-B), dopamine level, and histological examination of the substantia nigra were conducted following subacute MPTP exposure.<h4>Results</h4>Exposure to MPTP altered neurobehavioural performance, oxidative stress biomarkers, neuroinflammatory markers (IL-1β, TNF-α), and other assessed biochemical parameters, as evidenced by increased beam performance latency, bradykinesia, and a lower traction score. Significant (p < 0.05) increase in MDA level and decrease in SOD, CAT, and GSH were also observed. A significant (p < 0.05) increase was observed in IL-1β and TNF-α levels, and a decrease (p < 0.05) was observed in mitochondrial complex 1 activity, BDNF and dopamine levels. Nigral histological distortions were observed following MPTP exposure.<h4>Conclusion</h4>These findings confirm the established alterations in neurobehavioral, physiological and morphological features in the substantia nigra of MPTP-exposed Swiss mice. The study assesses early nigral alterations after subacute MPTP exposure and supports the use of this model for investigating MPTP-induced neurotoxicity.
Background
The study investigates the impact of MPTP, a neurotoxin used to model Parkinson's disease, on the substantia nigra, a brain region critical for movement. Previous research has shown that MPTP exposure leads to dopaminergic neuron degeneration, but the specific biochemical and structural changes remain to be fully characterized. Understanding these alterations is essential for developing potential therapeutic strategies for movement disorders.
Methods
The study utilized a controlled experimental design with 12 adult male Swiss mice divided into two groups. One group received normal saline while the other received MPTP (30 mg/kg i.p.) daily for 5 days. Neurobehavioral assessments and biochemical analyses were conducted 24 hours after the last MPTP administration to evaluate the effects on various parameters.
Results
Exposure to MPTP resulted in significant alterations in neurobehavioral performance and biochemical markers. Specifically, there was a significant (p < 0.05) increase in MDA levels and a decrease in SOD, CAT, and GSH levels. Additionally, increases in IL-1β and TNF-α levels were significant (p < 0.05), alongside a decrease in mitochondrial complex 1 activity, BDNF, and dopamine levels.
Interpretation
The findings align with existing literature that demonstrates MPTP's neurotoxic effects, particularly in inducing oxidative stress and neuroinflammation. While the statistical significance of the results is noted, the clinical relevance remains uncertain due to the small sample size and the use of an animal model. These limitations suggest caution in extrapolating the findings to human conditions.
Key findings
- Significant (p < 0.05) increase in MDA level and decrease in SOD, CAT, and GSH.
- Significant (p < 0.05) increase in IL-1β and TNF-α levels.
- Significant (p < 0.05) decrease in mitochondrial complex 1 activity, BDNF, and dopamine levels.
- Increased beam performance latency and bradykinesia were noted.
- Lower traction score observed in MPTP-treated mice.
Limitations
- small n=12 study
- rodent only, no human data
- short follow-up after MPTP exposure
- single-site study